Abstract
BACKGROUND While the clinical benefits of multimodal prehabilitation in cancer patients are well defined, the underlying immune modulations have not been studied. The objective of this study was to examine how prehabilitation can alter lung cancer immunity.
METHODS Newly diagnosed lung cancer patients were referred to the prehabilitation clinic for preoperative personalized multimodal intervention (exercise training, nutritional optimization, and anxiety reduction) and blood samples were collected at baseline and surgery. Tumor samples were collected at surgery and compared to matched control samples from patients who did not receive prehabilitation. An animal model was used to study prehabilitation and tumor growth kinetics.
RESULTS Twenty-eight lung cancer patients who underwent multimodal prehabilitation were included (McGill University Health Centre Research Ethics Board #2023-9005). After prehabilitation, patient-isolated peripheral blood mononuclear cells (PBMCs) showed significantly increased cytotoxicity against cancer cells (p < 0.0001) and significantly increased circulating natural killer (NK) cells in cohort (p = 0.0290) and paired analyses (p = 0.0312). Compared to matched controls, patients who received prehabilitation had significantly more intra-tumor NK cells (p = 0.0172). In vivo, we observed a significant increase in circulating NK cells (p = 0.0364) and slower tumor growth (p = 0.0396) with prehabilitation. When NK cells were depleted in prehabilitated mice, we observed a decrease in the protective effects of prehabilitation (p = 0.0314) and overall, we observed a significant correlation between circulating NK cells and reduced tumor volume (p = 0.0203, r = -0.5143).
CONCLUSIONS Multimodal prehabilitation may play a role in antitumor immunity by increasing peripheral and tumour-infiltrating NK cells leading to a reduced cancer burden. Future studies on the protective effect of prehabilitation on postoperative immunity should be conducted.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
None to declare.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was conducted in accordance with the Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans (2014), as well as with the requirements set out in the applicable standard operation procedures of the Research Institute of the McGill University Health Centre and was approved by the McGill University Health Centre Research Ethics Board (2023-9005). Samples were obtained from patients who had consented to participate in the Thoracic Oncology Clinical Database and Biobank (2014-1119).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
List of abbreviations
- 6MWD
- 6-minute walk distance (m)
- 6MWT
- 6-minute walk test
- A549
- human lung adenocarcinoma cell line
- ECM
- extracellular matrix
- FFPE
- formalin-fixed paraffin-embedded
- GFP
- green fluorescent protein
- HIIT
- high-intensity interval training
- LLC1
- Lewis Lung cancer mouse cell line
- MDSC
- myeloid derived suppressor cell
- NK
- cell natural killer cell
- NSCLC
- non-small cell lung cancer
- PBMC
- peripheral blood mononuclear cells
- TAM
- tumour associated macrophage
- TME
- tumour microenvironment
